WO2025201979 - A METHOD FOR DEFATTENING A STEATOTIC LIVER EX VIVO BY PERFUSION USING A PI4KB INHIBITOR

National phase entry is expected:
Publication Number WO/2025/201979
Publication Date 02.10.2025
International Application No. PCT/EP2025/057453
International Filing Date 19.03.2025
Title **
[English] A METHOD FOR DEFATTENING A STEATOTIC LIVER EX VIVO BY PERFUSION USING A PI4KB INHIBITOR
[French] PROCÉDÉ D'ÉLIMINATION EX VIVO DE LA GRAISSE D'UN FOIE ATTEINT DE STÉATOSE HÉPATIQUE PAR PERFUSION À L'AIDE D'UN INHIBITEUR DE PI4KB
Applicants **
ETH ZURICH
Inventors
WOLFRUM, Christian
TIBBITT, Mark
DING, Lianggong
HOFFMANN, Waldemar
HUWYLER, Florian
BINZ, Jonas
Priority Data
24166005.9   25.03.2024   EP
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting2390
EPO Filing, Examination, Granting9564
Japan Filing, Examination, Granting2155
South Korea Filing, Examination, Granting2071
USA Filing, Examination, Granting4740
MasterCard Visa
Total: 20,920
Contact Us
Abstract[English] The present invention relates to a method for defattening a steatotic liver ex vivo, the method comprising perfusing a steatotic liver graft in a perfusion step using a perfusate comprising a PI4KB inhibitor as specified or a pharmaceutically acceptable salt or solvate thereof.[French] La présente invention concerne un procédé d'élimination ex vivo de la graisse d'un foie atteint de stéatose hépatique, le procédé comprenant la perfusion d'un greffon de foie stéatosique dans une étape de perfusion à l'aide d'un perfusat contenant un inhibiteur de PI4KB tel que spécifié ou un sel ou solvate pharmaceutiquement acceptable de celui-ci.